Graft-versus-host disease epidemiology and demographics
|
Graft-versus-host disease |
|
Differentiating Graft-versus-host disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Graft-versus-host disease epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Graft-versus-host disease epidemiology and demographics |
|
FDA on Graft-versus-host disease epidemiology and demographics |
|
CDC on Graft-versus-host disease epidemiology and demographics |
|
Graft-versus-host disease epidemiology and demographics in the news |
|
Blogs on Graft-versus-host disease epidemiology and demographics |
|
Risk calculators and risk factors for Graft-versus-host disease epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]
Overview
Epidemiology and Demographics
GvHD affects 30*70% of patients who undergo allogeneic transplant.[1] It is not an uncommon complication of stem cell transplant. It tends to occur more often in patients who have less genetic similarity compared to their donors. It typically occurs within the first 100 days of transplant (acute GvHD) (approximately 90-95% of cases), though it can also occur after the 100-day time point (chronic GvHD). The median time of onset is approximately 5 months.[1]
References
- ↑ 1.0 1.1 Lee SJ (2010). "Have we made progress in the management of chronic graft-vs-host disease?". Best Pract Res Clin Haematol. 23 (4): 529–35. doi:10.1016/j.beha.2010.09.016. PMC 3053022. PMID 21130418.